cGMP clinical batches of tablet and capsule dosage forms

Ascendia pharmaceuticals offers stability chambers. Features: it is an analytical instrument for testing pharmaceutical formulations. Contact us for more information.

Ascendia pharmaceuticals offers tablet compression. Features: it is an equipment for producing pharmaceutical formulations. Contact us for more information.

Ascendia pharmaceuticals offers total organic carbon (toc) analyzer. Features: it is an analytical instrument for testing pharmaceutical formulations. Contact us for more information.

Ascendia pharmaceuticals offers usp dissolution. Features: it is an analytical instrument for testing pharmaceutical formulations. Contact us for more information.

Ascendia pharmaceuticals offers amorsol. Features: it is a technology for the production of amorphous solid dispersions. Solid dispersions are used to increase the dissolution rate, a limiting factor for the absorption of many compounds in development today. Contact us for more information.

Ascendia pharmaceuticals offers cGMP clinical batches of injectable dosage forms. Features: a dedicated, self-contained cleanroom for conducting sterile manufacturing and fill processes is maintained. Contact us for more information.

Ascendia pharmaceuticals offers emulsol. Features: it is a technology for production of oil-in-water nano-emulsions. Nano-emulsions are meta-stable, and a high level of input energy is required to produce a nano-emulsion. Contact us for more information.

Ascendia pharmaceuticals offers lyophilization. Features: it is an equipment for producing pharmaceutical formulations. Contact us for more information.

Ascendia pharmaceuticals offers micro-fluidizer. Features: it is an equipment for producing pharmaceutical formulations. Contact us for more information.

Ascendia pharmaceuticals offers nano-particle bead-milling. Features: it is an equipment for producing pharmaceutical formulations. Contact us for more information.

Ascendia pharmaceuticals offers nanosol. Features: it is a technology for the production of nano-sized drug particles. Formulation of a drug substance in nano-particle form significantly increases the surface area available for dissolution. Contact us for more information.

NanoSol is a technology for the production of nano-sized drug particles. Formulation of a drug substance in nano-particle form significantly increases the surface area available for dissolution.  A ten-to-twenty-fold increase in surface area can result from reducing particle size from a micronized dru...

Transformative technologies and the opportunities afforded by the COVID-19 pandemic have spurred investment in the life sciences outsourcing sector, according to a panel of industry experts speaking at CPHI North America on Monday.

Pharma R&D productivity has remained stagnant in the new millennium, despite record industry growth. While new technology has improved productivity in nearly every other sector, efficiency in pharmaceutical R&D is declining (or as described by MedCity News — “broken”).What obstacles are in the way of improving productivity in the pharmaceutical industry? How can we meet these challenges? At Ascendia Pharma, we’re proud to have innovative strategies in place to help our clients get their drugs from R&D to market faster.

Bringing a new drug—or a new formula—to market is an exciting time for pharmaceutical companies, but getting the formulation correct can be challenging. Low aqueous solubility is a top concern encountered with formulation development of new chemical entities (NCEs). Improper drug solubility can lead to suboptimal drug delivery and absorption, resulting in ineffective drug efficacy and side effects. That's why solubility of drugs must be evaluated in the early stages of drug discovery.

Nano-formulation of poorly water-soluble drugs has brought two proven benefits to commercial drug products. One is it enhances drug dissolution and oral bioavailability. Second, nano-formulation increases drug loading and release duration for parenteral drug delivery. In the June issue of issue of Drug Development & Delivery, Ascendia Pharma CEO Jim Huang, Ph.D., discusses one method of preparing nanosuspensions in his Formulation Forum column.